Recent innovations have created many new things. Among them?
The position of “Chief Psychedelic Officer” for a public company.
Massive strides forward in the arena of capital markets have resulted in a new position, within a new industry, in a new era of scientific research.
Forward-thinking government officials have granted psychedelics the opportunity to be researched for their benefits, which have the potential to include physical improvement, addiction management, mental health enhancement, and more. There are further reaching implications for the study of psychedelic medicine but in order to realize them, you need the right team in place.
NeonMind Biosciences (Canada: NEON) has brought on Trevor Millar, a celebrity in the psychedelic world, to help boost the team to the next level.
Who is Trevor Millar?
Trevor Millar is a social entrepreneur and long-time advocate of psychedelic science as a treatment for addiction, with specific focus on opiate usage in the downtown eastside of Vancouver.
Millar has been on the Board of Directors for the Multidisciplinary Association of Psychedelic Studies (MAPS) in Canada since 2018 and was Chair of the Board for two of those years. The organization is one of the global leaders in psychedelic research, which has historically raised $110M for investigation and lobbying on the topic.
Our team has hosted Trevor Millar at our live events and, even beyond his resume, he is a passionate advocate for the industry. His mission to embrace and understand the benefits of psychedelic medicine is inspiring, and we know that he aligns himself with the causes that he cares deeply about. We’re extremely excited to see him on the team.
What is a Chief Psychedelic Officer?
As noted in the press release, there are several key areas that Millar will take on at NeonMind, including:
- Developing policy
- Establishing multi-party projects that use psychedelics to address community health needs such as addiction
- Assisting NeonMind in developing safe and effective protocols for psychedelic treatments for one or more human clinical trials to be submitted for approval to Health Canada and
- Working within the psychedelic industry to build alliances and partnerships and to identify potential acquisition targets for NeonMind
In general, Trevor Millar is going to be applying his experience and understanding of the psychedelic industry to help guide NeonMind through the next steps in the research and testing period.
“Trevor Millar has immense experience in providing education about the risks and benefits of psychedelics and has been a leader in the growth of the psychedelic industry,” says NeonMind CEO Penny White. “We are honoured to welcome him to our management team to help NeonMind develop our plan to legally and safely commercialize psychedelic drugs.”
Disclaimer: NeonMind is a communications client of Edge Investments, and we own shares in the company.